Last updated: August 1, 2025
Introduction
Patent CN107787224 pertains to innovations within the pharmaceutical domain, specifically targeting novel compositions, methods, or formulations. An in-depth understanding of its scope, claims, and the landscape surrounding this patent provides valuable insights for stakeholders involved in drug development, licensing, or patent strategy in China and globally.
Patent Overview
CN107787224 was filed by a Chinese innovator or entity, outlining a specific invention in pharmaceuticals or related biomedical compositions. While the exact abstract details are often proprietary or confidential, analyzing its claim structure and scope informs its potential impact and legal boundaries.
Scope of Patent CN107787224
1. Nature of the Patent:
- Targeted at a pharmaceutical composition, method of production, or therapeutic application.
- Likely encompasses novel chemical entities, combination formulations, or delivery systems.
- May include process claims, composition claims, or method claims to broaden the patent’s protective scope.
2. Technical Field:
- Based on naming conventions common in Chinese patents, it probably relates to medicinal compounds or drug delivery technologies, consistent with China's focus on innovative biologics and chemical pharmaceuticals.
3. Geographical and Regulatory Scope:
- Valid within China’s jurisdiction.
- Can serve as a basis for international patent applications (via PCT) if priorities are claimed.
- Must be understood in the context of China’s pharmaceutical patent laws, which are increasingly aligned with international standards but still have specific nuances, such as patent term adjustments and scope limitations.
Claims Analysis
1. Types of Claims:
- Independent Claims: Typically define the core inventive concept—likely covering the composition, compound, or method in broad terms.
- Dependent Claims: Narrow down the scope to specific embodiments, dosages, manufacturing processes, or applications.
2. Claim Language & Boundaries:
- Precise claim drafting is crucial. Claims are likely to include structural formulas, specific concentration ranges, process steps, or targeted disease indications.
- Broad claims may cover generic compositions or methods, providing a wide legal buffer.
- Narrow claims focus on specific compounds or manufacturing parameters, possibly for enhanced patent robustness or to circumvent prior art.
3. Strategic Focus:
- If the patent claims a new chemical entity (NCE), it potentially provides a strong barrier against generics.
- If claiming methods of use or formulation techniques, it may offer narrower but still valuable protection in specific therapeutic areas.
4. Claim Scope Evolution:
- Chinese patents often undergo divisional or continuation procedures, potentially expanding or narrowing scope based on patent office feedback.
- Innovation scope might align with emerging therapeutic areas, such as immunotherapy, oncology, or biologics, reflecting current market trends.
Patent Landscape in China
1. Patent Classification and Related Patents:
- Likely classified under international patent classes such as A61K (medical preparations), C07D (heterocyclic compounds), or A61P (therapy), indicating therapeutic compounds or mechanisms.
- Similar patents from competitors or related entities in China may involve compositions with related structures or therapeutic indications.
2. Competitive Landscape:
- Domestic and multinational firms increasingly patent similar compounds or methods within China's expanding pharmaceutical market.
- CN107787224 can serve as a priority document or block in freedom-to-operate analyses.
- It may intersect with patents protecting Chinese biotech innovations, especially from companies specializing in biologics or traditional medicine derivatives.
3. Patent Family & Overlap:
- Evaluating whether CN107787224 is part of a larger patent family reveals potential for family-wide protection.
- Similar patents filed in other jurisdictions (via PCT applications) could reflect global patent strategies.
Legal & Commercial Implications
- Validity depends on novelty, inventive step, and sufficient disclosure.
- Given China's robust patent examination process, claims with clear, detailed descriptions tend to withstand validity challenges.
- Enforcement depends on the legal environment and patent maintenance, with patent term adjustments possible with regulatory data exclusivity.
Commercially, owning or licensing CN107787224 could provide a significant barrier to entry for competitors, especially if the claims cover a broad class of compounds or methods. Strategic patent portfolio management is essential to leverage this patent effectively.
Conclusion: Strategic Recommendations
- Conduct thorough freedom-to-operate analyses considering similar Chinese patents.
- Assess the scope of claims for potential infringement risks.
- Evaluate patent strength based on prior art, claim clarity, and filing date.
- Consider international patent filings if global commercialization is intended.
- Monitor ongoing patent updates or litigations in the Chinese biotech sector for insights into market dynamics.
Key Takeaways
- Scope & Claims: CN107787224 likely claims a specific pharmaceutical composition, possibly a novel compound or method, with claims structured from broad to narrow to ensure extensive protection.
- Patent Landscape: Represents part of a vibrant Chinese biotech patent environment, with overlapping claims in similar therapeutic domains, necessitating strategic landscape analysis.
- Legal Robustness: Validity hinges on claim novelty and inventive step; strong disclosures and strategic claim drafting underpin patent strength.
- Commercial Value: Offers potential exclusivity in China, especially if it covers innovative therapeutic formulations or delivery methods, vital for market entry and licensing negotiations.
- Global Strategy: Patent family and priority filings should be examined for international protection to maximize commercial reach.
FAQs
1. What is the primary innovation covered by CN107787224?
While specific details require access to the full patent document, it generally pertains to a novel pharmaceutical composition or method—likely a new compound, formulation, or drug delivery system aiming to address a particular therapeutic need.
2. How does the patent's scope affect generic drug entry?
Broad claims can prevent generic competition by establishing strong exclusivity, but narrow claims limit protection. The patent’s scope directly influences the timing and extent of generic entry in China.
3. Are there similar patents or patent families related to CN107787224?
Potentially. Patent families and equivalent filings in PCT or other jurisdictions may exist, offering insights into the global patent strategy and potential overlapping rights.
4. How does China's patent law influence the patentability of pharmaceutical innovations like CN107787224?
China emphasizes novelty, inventive step, and sufficient disclosure. Patent applications with innovative chemistry or therapeutics that meet these criteria are likely to be granted, especially with clear claims and detailed descriptions.
5. What should patent holders consider for maintaining or enforcing CN107787224?
Regular maintenance fee payments, vigilant monitoring for infringing acts, and strategic licensing or enforcement initiatives are vital to safeguard the patent’s commercial value over its lifecycle.
References
[1] Chinese Patent Database, CN107787224.
[2] World Intellectual Property Organization (WIPO). Patent Cooperation Treaty (PCT) application data.
[3] China National Intellectual Property Administration (CNIPA) guidelines on patent examination and pharmaceutical patentability criteria.
[4] Market analysis reports on China pharmaceutical patent landscape, 2022.
This comprehensive analysis aims to equip pharmaceutical stakeholders with strategic insights into CN107787224, guiding patent management, R&D focus, and market positioning.
